Nomura Holdings Inc Insmed Inc Transaction History

Nomura Holdings Inc

$41.1 Billion
Q3 2024

A detailed history of Nomura Holdings Inc transactions in Insmed Inc stock. As of the latest transaction made, Nomura Holdings Inc holds 80,000 shares of INSM stock, worth $5.91 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

80,000

Previous 234,500 65.88%

Holding current value

$5.91 Million

Previous $15.7 Million 62.83%

% of portfolio

0.01%

Previous 0.03%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$23.42 - $31.74 $257,854 - $349,457	11,010 New	11,010 $341,000
Q2 2022 Aug 15, 2022	BUY	$17.07 - $25.71 $42,606 - $64,172	2,496 New	2,496 $52,000
Q2 2021 Aug 16, 2021	SELL	$24.17 - $36.01 $338,380 - $504,140	-14,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$32.28 - $44.3 $451,920 - $620,200	14,000 New	14,000 $475,000
Q4 2020 Feb 16, 2021	SELL	$31.45 - $40.54 $505,999 - $652,248	-16,089 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$26.0 - $34.5 $418,314 - $555,070	16,089 New	16,089 $519,000
Q1 2020 May 14, 2020	SELL	$13.63 - $33.98 $1.18 Million - $2.93 Million	-86,313 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$16.12 - $24.98 $177,529 - $275,104	11,013 Added 14.63%	86,313 $2.06 Million
Q3 2019 Nov 14, 2019	SELL	$15.49 - $25.78 $1.72 Million - $2.86 Million	-111,100 Reduced 59.6%	75,300 $1.3 Million
Q2 2019 Aug 14, 2019	BUY	$23.0 - $32.19 $4.08 Million - $5.71 Million	177,500 Added 1994.38%	186,400 $4.81 Million
Q1 2019 May 14, 2019	SELL	$13.91 - $31.15 $2.8 Million - $6.26 Million	-201,100 Reduced 95.76%	8,900 $259,000
Q3 2018 Nov 14, 2018	BUY	$18.95 - $28.08 $3.98 Million - $5.9 Million	210,000 New	210,000 $3.3 Million

Others Institutions Holding INSM

# of Institutions

467

Shares Held

182M

Call Options Held

2.27M

Put Options Held

3.33M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Holdings Inc with notifications on news.

Account

Nomura Holdings Inc Insmed Inc Transaction History